ONL Therapeutics Advances Global Trial for Vision Loss Therapy

ONL Therapeutics Advances Global Trial for Vision Loss Therapy

By, Admin 17 March 2026

A key milestone has just been reached in the fight against one of the leading causes of blindness.

ONL Therapeutics announced that the first European patient has been randomized in its Phase 2 GALAXY trial, evaluating an experimental therapy for Geographic Atrophy (GA).

This marks the official expansion of the trial into Europe, with the first site activated in Switzerland.

What Is the GALAXY Trial?

GALAXY is a global Phase 2 clinical trial designed to assess the safety and effectiveness of:

  • Xelafaslatide (formerly ONL1204)

The study will:

  • Enroll ~324 patients
  • Span across the U.S., Canada, and Europe
  • Evaluate multiple dosing strategies and treatment frequencies

Trial Design at a Glance

  • Delivery method: Intravitreal injection (directly into the eye)
  • Dosing arms: Two dose levels
  • Treatment intervals: Every 12 or 24 weeks
  • Primary endpoint:
    • Reduction in growth rate of GA lesions at 48 weeks
  • Extended follow-up: Up to 72 weeks

Why This Matters: A Disease With Limited Options?

Geographic Atrophy is an advanced stage of Age-related Macular Degeneration (AMD), a leading cause of vision loss globally.

Key challenges:

  • Progressive and irreversible damage to the retina
  • Loss of central vision (critical for reading and driving)
  • Very limited treatment options, especially in Europe

As populations age, the burden of AMD—and GA in particular—is rising rapidly.

A New Approach: Neuroprotection Instead of Just Slowing Damage

What makes Xelafaslatide different is its mechanism of action. It targets the Fas pathway, which plays a major role in retinal cell death.

Why this is important:

  • Retinal cell death is the root cause of vision loss
  • Protecting these cells could preserve vision, not just delay decline
  • Represents a potential first-in-class neuroprotective therapy

Built on Promising Early Data

The GALAXY trial builds on earlier studies showing:

  • Favorable safety and tolerability
  • Encouraging efficacy signals after six months

The drug has already been tested across multiple conditions, including:

  • Geographic atrophy (Phase 1b completed)
  • Open-angle glaucoma
  • Retinal detachment (with orphan drug designation from the U.S. Food and Drug Administration)

A Complex Global Trial in Motion

With Europe now active, ONL Therapeutics is executing a multi-region clinical strategy:

  • Simultaneous enrollment in North America and Europe
  • Coordination across multiple regulatory environments
  • Scaling toward full patient enrollment

This reflects growing confidence in both the therapy and the development program.

The Bigger Picture: Rising Need for Vision Preservation

Age-related Macular Degeneration is becoming a major global health concern due to:

  • Aging populations
  • Lifestyle risk factors (smoking, obesity, poor diet)
  • Increasing genetic awareness

And because GA affects the macula, even small disease progression can severely impact daily life.

Final Take

The first European patient enrollment in the GALAXY trial is more than a procedural milestone. It signals real momentum behind a therapy that could protect vision at its source.

If successful, Xelafaslatide could redefine how we treat retinal diseases—shifting from slowing damage to actively preserving sight.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!